<code id='3E74AEDDD7'></code><style id='3E74AEDDD7'></style>
    • <acronym id='3E74AEDDD7'></acronym>
      <center id='3E74AEDDD7'><center id='3E74AEDDD7'><tfoot id='3E74AEDDD7'></tfoot></center><abbr id='3E74AEDDD7'><dir id='3E74AEDDD7'><tfoot id='3E74AEDDD7'></tfoot><noframes id='3E74AEDDD7'>

    • <optgroup id='3E74AEDDD7'><strike id='3E74AEDDD7'><sup id='3E74AEDDD7'></sup></strike><code id='3E74AEDDD7'></code></optgroup>
        1. <b id='3E74AEDDD7'><label id='3E74AEDDD7'><select id='3E74AEDDD7'><dt id='3E74AEDDD7'><span id='3E74AEDDD7'></span></dt></select></label></b><u id='3E74AEDDD7'></u>
          <i id='3E74AEDDD7'><strike id='3E74AEDDD7'><tt id='3E74AEDDD7'><pre id='3E74AEDDD7'></pre></tt></strike></i>

          leisure time

          leisure time

          author:comprehensive    Page View:6536
          Photograph of the logo for BIO, the Biotechnology Innovation Organization, at the BIO International Convention at the Boston Convention and Exhibition Center in 2023
          BIO is proceeding with a restructuring after its new CEO took over. Lane Turner/The Boston Globe

          WASHINGTON — The Biotechnology Innovation Organization on Monday is announcing a significant restructuring accompanied by a shakeup, according to five sources familiar with the planning.

          A few senior leaders are expected to depart as part of the reorganization. Chief Science Officer Cartier Esham, Chief Public Affairs and Marketing Officer Rich Masters, and Chief Policy Officer John Murphy are expected to leave, four sources said. 

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Anesthesiologist group: stop taking Ozempic before surgery
          Anesthesiologist group: stop taking Ozempic before surgery

          EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

          read more
          FDA rejects Alnylam's heart disease treatment over insufficient data
          FDA rejects Alnylam's heart disease treatment over insufficient data

          KristofferTripplaar/SipaUSA/APTheFoodandDrugAdministrationrejectedanAlnylamPharmaceuticals’therapyfo

          read more
          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more

          Chemotherapy drug shortage eases slightly but still widespread

          AdobeTheshortageofcancerdrugsisnotgoingaway,butitmaybeeasingslightly,anewnationalsurveysuggests.Base